Jennifer Buell - 13 Oct 2021 Form 3 Insider Report for MiNK Therapeutics, Inc. (INKT)

Role
President, Chief Executive Officer Exhibit List: Exhibit 24 - Power of Attorney, Director
Signature
/s/ Christine Klaskin, attorney-in-fact
Issuer symbol
INKT
Transactions as of
13 Oct 2021
Net transactions value
$0
Form type
3
Filing time
20 Oct 2021, 18:53:35 UTC
Previous filing
02 Jul 2021
Next filing
25 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding INKT Common Stock 208,725 13 Oct 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding INKT Stock Option (Right to Buy) 13 Oct 2021 Common Stock 347,875 $0.0100 Direct F1
holding INKT Stock Option (Right to Buy) 13 Oct 2021 Common Stock 556,600 $3.03 Direct F2
holding INKT Restricted Stock Units 13 Oct 2021 Common Stock 695,750 $0.000000 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents an option to purchase shares of common stock, which vested as to 33% of the underlying shares on January 30, 2021, and with respect to the remainder, in eight equal quarterly installments thereafter, in each case, generally subject to continued employment.
F2 Represents an option to purchase shares of common stock, which vested as to 33% of the underlying shares on February 11, 2022, and with respect to the remainder, in eight equal quarterly installments thereafter, in each case, generally subject to continued employment.
F3 Represents restricted stock unit convertible into an equivalent number of shares of our common stock, which vest as to 100% of the underlying shares on September 27, 2023

Remarks:

President, Chief Executive Officer Exhibit List: Exhibit 24 - Power of Attorney